>Ginecología y Obstetricia de México
>Year 2014, Issue 04
Zárate-Treviño A, Hernández-Valencia M, Morán C, Manuel L, Saucedo R
Convenience clinic redefine polycystic ovary syndrome (Stein-Leventhal)
Ginecol Obstet Mex 2014; 82 (04)
PDF: 773.21 Kb.
In 1935 during a medical meeting behalf in New Orleans was presents
a study that included seven cases of women that suffered menstrual
dysfunctions, hirsutism and sterility, for laparotomy the description of
the ovaries had a pearly white color and it was hypertrophic, the cuneiform
resection in both ovaries resulted in correction of the menstrual
dysfunction and two of them got pregnancy later on, receiving the
name of polycystic ovary syndrome (PCOS). The technological advance
facilitates the hormonal analyses demonstrating the hyperandrogenism
existence and the mechanism of the anovulation, the PCOS showed poliquisto
be heterogeneous, reason why it was hindered to define it, this advanced
the current trend to question the existence of the PCOS and to
accept the convenience, either to change the name or to redefine it,
leaving it as a simple syndrome with several phenotypes. The endocrine
component includes abnormal secretion of insulin and consequently
outlying resistance to this hormone, likewise is hyperandrogenism,
dislipoproteinemia and obesity. The hormonal exams are unnecessary
for the diagnostic and treatment; it is convenient to demonstrate for
sonography the ovarian growth. Other dysfunctions like the congenital
suprarenal hyperplasia, hyperprolactinemia and hypotiroidism should
be discarded. The treatment should be individualized with relationship
to the reason of the consultation and the patients age. It has not been
demonstrated that the sensibilitizers use to the insulin avoids long
term cardiovascular illness and diabetes. Therefore, the phenotype is
heterogeneous with a fickle metabolic component and for it has arisen
the restlessness of a better definition of the SPO.
||polycystic ovary syndrome, menstrual dysfunction, hyperandrogenism, phenotypes expression.
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181- 191.
Stein IF, Cohen MR. Surgical treatment of bilateral polycystic ovaries, amenorrhea and sterility. Am J Obstet Gynecol 1939;38:465-480.
Mahesh VB, Greenblatt RB. Steroid secretion in the normal and polycystic ovaries. Recent Prog Hormon Res 1964;201:341-394.
Goldzieher JW, Green JA. The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962;22:325- 338.
Goldzieher JW. Polycystic ovarian disease. Clin Obstet Gyn 1973;16: 82-105.
Greenblatt RB. Chemical induction of ovulation. Fertil Steril 1961;12:402-405.
Greenblatt RB, Barfield WE, Jungck EC, Ray AW. Induction of ovulation with MRL/41 preliminary report. JAMA 1961;178:101.
Greenblat RB, Mahesh VB. The androgenic polycystic ovary. Am J Obstet Gyn 1976;125:712-726.
Goldzieher JW, Axelrod L. Clinical and biochemical feature of polycystic ovary disease. Fertil Steril 1963; 14:631-653.
Greenblatt RB, Zárate A, Mahesh VB. Inducción de la ovulación en el humano con citrato de clomifen. In: Induction and control of ovulation. C. Gual (ed), Excerpt a Med Inter Congress Series 104: 59, 1964.
Tyler ET, Winer J, Gotlib M, Olsom HJ. Effects of MR- 41 human male and female fertility studies. Clin Res 1962;10:119-122.
Zárate A, Hernandez-Ayup S, Rios A. Treatment of anovulation in the Stein-Leventhal syndrome. Analysis of 90 cases. Fertil Steril 1971;22:188-92.
Givens JR, et al. Remission of acanthosis nigricans associated with polycystic ovarian disease and stromal luteoma. J Clin Endocrinol Metab 1974;38:347-355.
Burghen GA, Givens JR, Kitbachi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113.
Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non-obese patients with Polycysticsn ovarian disease. J Clin Endocrinol Metab 1983;57:356.
Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006;91:22-24.
Alger M, Vázquez L, Mason M, Canales ES, Zárate A. Polycystic ovarian disease associated with hyperprolactinemia and defective metoclopramide response. Fertil Steril 1980;34:70.
Corenblum B, Taylor PJ. The hyperprolactinemic polycystic ovary syndrome may not be a distinct entity. Fertil Steril 1982;38:549-552.
Glintborg D, Andersen M, Hagen C, Frystk J, Hulstrom V, Flyvbjerg A. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006;155:337-345.
Zárate A, Hernández M, Austria E, Saucedo R, Hernández M. Diagnóstico de Menopausia prematura usando la medición de la hormona anti-mulleriana circulante. Ginec Obstet Mex 2011;79:303-307.
Cussons AJ, Stuckey BG, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol 2005;62: 289-95.
Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest 2010;64:247-280.
Zarate A, Canales ES, de la Cruz A, Soria J, Schally AV. Pituitary response to synthetic LH- RH in Stein-Leventhal Syndrome and functional amenorrhea. Obstet Gynecol 1973;41:803-808.
Yen SSC, Vela P, Rankin J. Inappropriate secretion of folliclestimulating hormone and luteinizing hormone in polycystic ovary disease. J Clin Endocrinol Metab 1970;30:435-442.
Yen SSC, Vandenberg G, Siler TM. Modulation of pituitary responsiveness to LRF by estrogen. J Clin Endocrinol Metab 1974;39:170-177.
>Ginecología y Obstetricia de México
>Year 2014, Issue 04